Related Experiment Video
Updated: Apr 30, 2026
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR
J M Granadino-Roldán1, C Obiol-Pardo2, M Pinto2
1Departamento de Química Física y Analítica, Universidad de Jaén, Campus "Las Lagunillas" s/n, 23071 Jaén, Spain.
Abstract:
Targeting the BCL6 protein is a promising therapeutic strategy for the treatment of B cell lymphomas. One approach to treat these diseases consists of finding drug candidates able to disrupt the interactions established between BCL6 and its corepressors. Thus, this work presents a thorough comparative analysis of the interactions between the BCL6 BTB (bric-a-brac tramtrack broad complex) protein domain and its SMRT, NcoR and BCOR corepressor BBDs (BCL6 binding domain) through molecular dynamics. Moreover, a theoretical structure is presented and checked for the BCL6(BTB)-NcoR(BBD) complex. Considering the BBDs to be composed of 17 amino acids, our analyses show the region involving residues 4-15 of these 17 to play a main role in the protein-corepressor interactions. Particularly SER(11) seems to have a high relevance as it establishes specific bonds with BCL6(BTB) and is one of the only two residues sequence equivalent for the three studied corepressors. From this study, 14 pharmacophoric points have been proposed divided in two groups which coincide with residues 4-11 and 11-15, being SER(11) a hinge point. This finding suggests the possibility of searching for 2 small molecule inhibitors, mimicking 8 and 7 pharmacophoric points, respectively, which could incorporate a hydrogen donor pharmacophoric point mimicking SER(11) in any or both molecules. In short, the present work aims to contribute further knowledge in the modeling of drugs mimicking BCL6(BTB)-corepressor complexes.
Insights
Researchers analyzed interactions between the BCL6 protein and its corepressors to develop new B cell lymphoma drugs. Key residues, particularly SER(11), are crucial for drug design targeting these protein-corepressor interactions.
Area of Science:
- Biochemistry
- Structural Biology
- Pharmacology
Background:
- Targeting the BCL6 protein is a key strategy for treating B cell lymphomas.
- Disrupting BCL6 interactions with corepressors is a promising therapeutic approach.
Purpose of the Study:
- To comparatively analyze interactions between the BCL6 BTB domain and SMRT, NcoR, and BCOR corepressor BBDs.
- To identify key residues and pharmacophoric points for drug design targeting BCL6-corepressor complexes.
Main Methods:
- Molecular dynamics simulations were used to study protein-corepressor interactions.
- A theoretical structure of the BCL6(BTB)-NcoR(BBD) complex was analyzed.
- Pharmacophoric points were identified based on key residue interactions.
Main Results:
- Residues 4-15 of the 17-amino acid BBDs are critical for BCL6 binding.
- SER(11) plays a significant role, forming specific bonds and being conserved across corepressors.
- 14 pharmacophoric points were identified, suggesting potential for dual small molecule inhibitors.
Conclusions:
- The study provides insights into BCL6(BTB)-corepressor interactions for drug discovery.
- SER(11) is a critical hinge point for designing inhibitors.
- The findings support the development of novel therapeutics for B cell lymphomas.
Related Concept Videos
01:49Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
01:49Conserved Binding Sites
02:04Co-activators and Co-repressors
01:30Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...